Inovio Pharmaceuticals, Inc. INO

Company Overview

Inovio Pharmaceuticals, Inc. is a U.S.-based biotechnology company focused on the research, development, and commercialization of DNA medicines and immunotherapies. The company operates primarily in the biotechnology and life sciences industries, with a focus on infectious diseases, oncology, and rare diseases. Inovio develops synthetic DNA-based therapeutics and vaccines designed to stimulate targeted immune responses using its proprietary delivery technologies. Its core revenue sources have historically included collaborative research agreements, government grants, licensing arrangements, and capital markets financing, as the company remains primarily in the clinical development stage.

The company’s principal strategic differentiator is its proprietary DNA medicine platform combined with its electroporation delivery systems, particularly the CELLECTRA® device technology used to deliver DNA plasmids into cells. Inovio was founded in 1979 and evolved through multiple corporate restructurings and technology acquisitions before focusing on DNA therapeutics and vaccine technologies in the 2000s. The company gained broader public visibility during the COVID-19 pandemic through development efforts related to its investigational vaccine candidate INO-4800, although the company’s broader pipeline spans oncology therapeutics, HPV-related diseases, and infectious disease candidates.